November 18, 2026
Health news, explained with evidence
LIVE

Cannabidiol Fails to Outperform Placebo for Behavioral Issues in Children with Intellectual Disabilities

🧠 AI Analysis 2 min read 👁 4

A new randomized clinical trial shows that cannabidiol (CBD) oil is no more effective than a placebo in treating severe behavioral problems among children with intellectual disabilities.

Cannabidiol Fails to Outperform Placebo for Behavioral Issues in Children with Intellectual Disabilities🧠AI Analysis

Photo: medpagetoday.com

Key points

  • Randomized trial evaluated CBD isolate versus placebo in 132 youths over 8 weeks
  • Results showed no statistically significant difference in irritability scores between groups
  • Adverse event rates were comparable between the CBD and placebo cohorts

A clinical trial conducted in Australia has found that cannabidiol (CBD) isolate is no more effective than a placebo at alleviating severe behavioral issues, such as aggression and self-injury, in children and adolescents with intellectual disabilities. Led by Daryl Efron, MD, of The Royal Children's Hospital in Victoria, the double-blind study evaluated 132 participants aged 6 to 18 over an eight-week treatment period. Researchers measured behavioral changes using the Aberrant Behavior Checklist, Irritability subscale, relying on parent reports.

Over the course of the study, both groups showed reductions in irritability scores, but the difference between the CBD group and the placebo group was not statistically significant. Specifically, scores dropped from 32.2 to 21.7 with CBD and from 30.0 to 19.2 with a placebo. Furthermore, adverse events occurred at similar rates across both cohorts, affecting roughly 60% to 63% of participants. Subgroup analyses, including a subset of patients with autism spectrum disorder who made up the majority of the trial, also revealed no advantage for the cannabinoid treatment.

Experts emphasize that these findings come with certain study limits, including a diverse patient population and a fixed daily dose of 10 mg/kg that was originally derived from epilepsy research rather than behavioral trials. Editorial commentators noted that the strong placebo response highlights the necessity of randomized controlled trials rather than relying on anecdotal evidence. Patients and caregivers should always consult a qualified healthcare provider before making any personal medical or treatment decisions.

What to know: A rigorous 8-week clinical trial found that purified CBD oil performed no better than a placebo in reducing severe behavioral challenges among youths with intellectual disabilities.

Source medpagetoday.com — medpagetoday.com/pediatrics/generalpediatrics/123911 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.